Trial Details

COMPLETED
Basic Information
Clinical ID c2656
Identifier NCT03154086
Trial Title A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
Trial URL Visit Original Page
Study Information
Study Results

YES

Conditions Irritable Bowel Syndrome
Interventions DRUG: GSK3352589|DRUG: Matching Placebo
Participant Information
Sponsor GlaxoSmithKline
City South Australia
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2017-05-17
Primary Completion Date 2018-03-05
Completion Date 2018-03-05